Skip to Main Content

Editor’s note: A recording of this conversation is embedded below. 

Eli Lilly was the first company to enter clinical trials with a drug designed to treat Covid-19. The medicine, a monoclonal antibody, will be tested for both treating and preventing infection in patients who have been exposed to the disease.

advertisement

“My expectation is if neutralizing antibodies work, and as I said I’m optimistic here, we’ll know within the next couple of months,” said Lilly CSO Daniel Skovronsky in a discussion with STAT’s Matthew Herper.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.